Loading...

Enzon Pharmaceuticals

DB:EZ1
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EZ1
DB
$10M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. The last earnings update was 62 days ago. More info.


Add to Portfolio Compare Print
  • Enzon Pharmaceuticals has significant price volatility in the past 3 months.
EZ1 Share Price and Events
7 Day Returns
0%
DB:EZ1
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-5.6%
DB:EZ1
-7.4%
DE Biotechs
-5.6%
DE Market
EZ1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Enzon Pharmaceuticals (EZ1) 0% 0% -5.6% -5.6% -64.5% -73.6%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • EZ1 outperformed the Biotechs industry which returned -7.4% over the past year.
Price Volatility
EZ1
Industry
5yr Volatility vs Market

Value

 Is Enzon Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Enzon Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.17.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Enzon Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Enzon Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:EZ1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.13
OTCPK:ENZN Share Price ** OTCPK (2019-04-24) in USD $0.23
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Enzon Pharmaceuticals.

DB:EZ1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:ENZN Share Price ÷ EPS (both in USD)

= 0.23 ÷ 0.13

1.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enzon Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • Enzon Pharmaceuticals is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Enzon Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:EZ1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
6.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Enzon Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Enzon Pharmaceuticals's assets?
Raw Data
DB:EZ1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.34
OTCPK:ENZN Share Price * OTCPK (2019-04-24) in USD $0.23
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:EZ1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:ENZN Share Price ÷ Book Value per Share (both in USD)

= 0.23 ÷ 0.34

0.69x

* Primary Listing of Enzon Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enzon Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Enzon Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Enzon Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Enzon Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Enzon Pharmaceuticals, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Enzon Pharmaceuticals expected to grow at an attractive rate?
  • Enzon Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Enzon Pharmaceuticals's earnings growth is positive but not above the Germany market average.
  • Unable to compare Enzon Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:EZ1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:EZ1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 6.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:EZ1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:EZ1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 7 -1 6
2018-09-30 0 2 -1
2018-06-30 0 2 0
2018-03-31 7 6 4
2017-12-31 8 6 5
2017-09-30 9 5 0
2017-06-30 11 7 1
2017-03-31 7 5 -2
2016-12-31 8 3 -1
2016-09-30 11 4 16
2016-06-30 12 5 13
2016-03-31 15 8 16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Enzon Pharmaceuticals's earnings are expected to grow by 6.7% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Enzon Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:EZ1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Enzon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EZ1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.13
2018-09-30 -0.01
2018-06-30 0.00
2018-03-31 0.10
2017-12-31 0.12
2017-09-30 0.01
2017-06-30 0.03
2017-03-31 -0.05
2016-12-31 -0.03
2016-09-30 0.36
2016-06-30 0.30
2016-03-31 0.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Enzon Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Enzon Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Enzon Pharmaceuticals has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Enzon Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Enzon Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Enzon Pharmaceuticals's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Enzon Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (7.4% vs -46.2%)
  • Enzon Pharmaceuticals's earnings growth has not exceeded the Europe Biotechs industry average in the past year (7.4% vs 18.2%).
Earnings and Revenue History
Enzon Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Enzon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:EZ1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6.92 5.85 1.06
2018-09-30 -0.19 -0.57 1.18
2018-06-30 0.24 0.10 1.27
2018-03-31 6.95 4.49 1.35
2017-12-31 8.38 5.45 1.37
2017-09-30 9.22 0.37 1.17
2017-06-30 11.03 1.15 1.21
2017-03-31 6.53 -2.00 1.31
2016-12-31 8.31 -1.13 1.68
2016-09-30 10.65 15.99 2.37
2016-06-30 12.45 13.24 2.21
2016-03-31 15.28 15.98 2.29
2015-12-31 17.26 21.64 2.15
2015-09-30 20.30 14.94 1.17
2015-06-30 24.66 24.35 1.59
2015-03-31 27.30 27.45 2.46
2014-12-31 31.04 28.80 2.38
2014-09-30 32.15 28.47 3.76 0.19
2014-06-30 32.85 26.44 5.39 0.84
2014-03-31 33.24 24.28 6.40 1.14
2013-12-31 34.41 18.15 8.84 2.72
2013-09-30 38.55 7.51 10.04 6.88
2013-06-30 40.64 6.13 10.99 10.18
2013-03-31 42.32 0.68 12.95 15.47
2012-12-31 42.63 -2.78 13.68 20.89
2012-09-30 41.08 -2.65 14.71 24.80
2012-06-30 40.42 -15.93 15.60 31.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Enzon Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Enzon Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Enzon Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Enzon Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Enzon Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Enzon Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Enzon Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Enzon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Enzon Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Enzon Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Enzon Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Enzon Pharmaceuticals Company Filings, last reported 3 months ago.

DB:EZ1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 14.99 0.00 6.50
2018-09-30 8.11 0.00 6.73
2018-06-30 8.63 0.00 6.97
2018-03-31 8.83 0.00 7.24
2017-12-31 9.14 0.00 7.48
2017-09-30 8.68 0.00 4.32
2017-06-30 15.16 0.00 11.21
2017-03-31 10.98 0.00 8.08
2016-12-31 10.33 0.00 7.64
2016-09-30 21.58 0.00 12.90
2016-06-30 20.64 0.00 11.23
2016-03-31 19.61 0.00 9.74
2015-12-31 18.09 0.00 11.67
2015-09-30 16.65 0.00 20.26
2015-06-30 18.46 0.00 38.99
2015-03-31 36.77 0.00 34.80
2014-12-31 29.60 0.00 34.56
2014-09-30 28.22 0.00 28.99
2014-06-30 20.64 0.00 21.48
2014-03-31 13.77 0.00 14.86
2013-12-31 5.26 0.00 6.52
2013-09-30 19.78 0.00 21.69
2013-06-30 14.05 0.00 14.46
2013-03-31 79.46 115.85 199.31
2012-12-31 77.47 115.85 196.74
2012-09-30 179.72 115.85 278.44
2012-06-30 191.52 115.85 129.15
  • Enzon Pharmaceuticals has no debt.
  • Enzon Pharmaceuticals had no debt 5 years ago.
  • Enzon Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
  • Enzon Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Enzon Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Enzon Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Enzon Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Enzon Pharmaceuticals dividends.
If you bought €2,000 of Enzon Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Enzon Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Enzon Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:EZ1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Enzon Pharmaceuticals has not reported any payouts.
  • Unable to verify if Enzon Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Enzon Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Enzon Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Enzon Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Enzon Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Enzon Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Enzon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andrew Rackear
COMPENSATION $190,039
AGE 64
TENURE AS CEO 3.1 years
CEO Bio

Mr. Andrew Rackear, J.D., has been the Chief Executive Officer and Secretary of Enzon Pharmaceuticals Inc. since March 31, 2016. Mr. Rackear served as the General Counsel and Secretary of Enzon Pharmaceuticals Inc. since April 2010 until November 30, 2013 and also served as its Vice President and Head of Human Resources. Mr. Rackear served as the Chief Compliance Officer of Enzon Pharmaceuticals since September 2010. Mr. Rackear served as Secretary and General Counsel of APBiotech Inc. Mr. Rackear served as Senior Vice President of Legal Affairs, General Counsel of NPS Pharmaceuticals Inc. from November 15, 2007 to October 30, 2009 and its Secretary from November 2007 to October 30, 2009. Mr. Rackear served as Corporate Secretary of NPS Pharmaceuticals Inc. from November 15, 2007 to October 30, 2009. He joined NPS in July 2007 as its Associate General Counsel and served until November 2007. Previously, he served as Vice President and General Counsel of Chugai Pharma, USA since April 2005. He served as Vice President and General Counsel of Amersham Biosciences Corp. from 2001 to April 2005 and served as its Secretary. He joined Pharmacia Biotech in 1994 as General Counsel and previously served as Counsel of Pharmacia U.S. Inc. from 1993 to 1994. He served as Associate General Counsel of Sharp Electronics Corporation from 1985 to 1988. From 1980 to 1985 and 1988 to 1993, he was in private practice with Marks & Murase in New York City. He is a Member of the New York and New Jersey state bar associations. He holds a BA in History from the University of Rochester and earned his JD at New York University School of Law in 1980.

CEO Compensation
  • Andrew's compensation has increased by more than 20% in the past year.
  • Andrew's remuneration is about average for companies of similar size in Germany.
Management Team

Andrew Rackear

TITLE
CEO & Secretary
COMPENSATION
$190K
AGE
64
TENURE
3.1 yrs

Richard Feinstein

TITLE
VP of Finance & CFO
COMPENSATION
$173K
AGE
75
TENURE
5.3 yrs
Board of Directors Tenure

Average tenure and age of the Enzon Pharmaceuticals board of directors in years:

5.6
Average Tenure
43
Average Age
  • The tenure for the Enzon Pharmaceuticals board of directors is about average.
Board of Directors

Jonathan Christodoro

TITLE
Chairman
COMPENSATION
$40K
AGE
42
TENURE
5.4 yrs

Jennifer McNealey

TITLE
Director
COMPENSATION
$35K
AGE
45
TENURE
5.6 yrs

Odysseas Kostas

TITLE
Director
COMPENSATION
$35K
AGE
43
TENURE
5.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Enzon Pharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Feb 19 Buy Jonathan Couchman Individual 11. Feb 19 11. Feb 19 36,000 €0.22 €7,979
15. Feb 19 Buy Xstelos Holdings, Inc. Company 11. Feb 19 11. Feb 19 15,000 €0.22 €3,324
10. Jan 19 Buy Jonathan Couchman Individual 13. Apr 18 07. Jan 19 1,104,002 €0.23 €249,336
10. Jan 19 Buy Xstelos Holdings, Inc. Company 21. Dec 18 21. Dec 18 312,523 €0.24 €73,688
10. Jan 19 Buy Xstelos Holdings, Inc. Company 12. Nov 18 20. Dec 18 532,500 €0.21 €104,047
X
Management checks
We assess Enzon Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Enzon Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. Enzon Pharmaceuticals, Inc.was founded in 1981 and is headquartered in Cranford, New Jersey.

Details
Name: Enzon Pharmaceuticals, Inc.
EZ1
Exchange: DB
Founded: 1981
$9,204,839
44,214,603
Website: http://www.enzon.com
Address: Enzon Pharmaceuticals, Inc.
20 Commerce Drive,
Suite 135,
Cranford,
New Jersey, 07016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK ENZN Common Stock Pink Sheets LLC US USD 15. Feb 1984
DB EZ1 Common Stock Deutsche Boerse AG DE EUR 15. Feb 1984
Number of employees
Current staff
Staff numbers
0
Enzon Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 20:51
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2019/02/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.